Colombotech Bio-B Sees Over 3% Surge in Stock Price After Earnings; Mid-Year Revenue Reaches $950 Million

Colombotech Bio-B (06990) saw its stock price surge 3.18% after earnings, currently trading at HK$461 million with a turnover of HK$1526 million.

On August 18th, Colombotech Bio-B released its mid-year results for the first half of 2025, which saw the company record revenue of RMB 9.5 billion (same below), down 31.3% year-on-year; research and development expenses of RMB 6.12 billion, down 6.3% year-on-year; and a net loss attributable to shareholders of RMB 1.45 billion; with each share losing 0.64 yuan.

The announcement noted that the company has obtained approval for the listing of sac-TMT (Jiateli?), Tagorli single antibody, and Xi Tao Xie single antibody N01 (Dateli?) from relevant authorities, and has begun its commercialization. Based on the pipeline of various late-stage projects, the company expects to launch its product Bodekuo Dazhu single antibody (Shuteli?) in China's market by the end of 2025 after obtaining regulatory approval.

Commercial sales revenue for the first half of 2025 reached RMB 3.098 billion, with Jiateli? accounting for 97.6%. All accounts receivable from pharmaceutical sales were collected within the period, and cash flow was high-efficiency and stable.